Wave Life Sciences Ltd. 2025-2026 Proxy Voting Records

Description as filed by funds: The election of the nominees for director: Adrian Rawcliffe

Wave Life Sciences Ltd.’s own tally for this item (“Elect Director: Adrian Rawcliffe”): 130,337,320 for, 285,647 against, per its Form 8-K filed August 11, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 55 asset managers below reported 28,274,133 for, 437 against, 6,157 abstained.

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

Description as filed by funds: The election of the nominees for director: Aik Na Tan

Wave Life Sciences Ltd.’s own tally for this item (“Elect Director: Aik Na Tan”): 130,362,062 for, 269,697 against, per its Form 8-K filed August 11, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 55 asset managers below reported 28,274,570 for, 6,157 abstained.

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

Description as filed by funds: The election of the nominees for director: Christian Henry

Wave Life Sciences Ltd.’s own tally for this item (“Elect Director: Christian Henry”): 111,549,230 for, 19,074,532 against, per its Form 8-K filed August 11, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 85% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 55 asset managers below reported 14,948,481 for, 13,326,089 against, 6,157 abstained.

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

Description as filed by funds: The election of the nominees for director: Gregory L. Verdine, Ph.D.

Wave Life Sciences Ltd.’s own tally for this item (“Elect Director: Gregory L. Verdine, Ph.D.”): 130,098,845 for, 521,198 against, per its Form 8-K filed August 11, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 55 asset managers below reported 28,245,074 for, 29,496 against, 6,157 abstained.

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

Description as filed by funds: The election of the nominees for director: Heidi L. Wagner, J.D.

Wave Life Sciences Ltd.’s own tally for this item (“Elect Director: Heidi L. Wagner, J.D.”): 125,980,141 for, 4,281,064 against, per its Form 8-K filed August 11, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 55 asset managers below reported 27,284,889 for, 749,681 against, 6,157 abstained.

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

Description as filed by funds: The election of the nominees for director: Ken Takanashi

Wave Life Sciences Ltd.’s own tally for this item (“Elect Director: Ken Takanashi”): 124,467,167 for, 6,024,248 against, per its Form 8-K filed August 11, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 55 asset managers below reported 23,838,161 for, 4,436,409 against, 6,157 abstained.

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

Description as filed by funds: The election of the nominees for director: Mark H. N. Corrigan, M.D.

Wave Life Sciences Ltd.’s own tally for this item (“Elect Director: Mark H.N. Corrigan, M.D.”): 129,548,443 for, 1,084,930 against, per its Form 8-K filed August 11, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 55 asset managers below reported 28,274,133 for, 437 against, 6,157 abstained.

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

Description as filed by funds: The election of the nominees for director: Paul B. Bolno, M.D., MBA

Wave Life Sciences Ltd.’s own tally for this item (“Elect Director: Paul B. Bolno, M.D., MBA”): 129,131,201 for, 1,501,235 against, per its Form 8-K filed August 11, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 55 asset managers below reported 28,274,570 for, 6,157 abstained.

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

Description as filed by funds: The election of the nominees for director: Peter Kolchinsky, Ph.D.

Wave Life Sciences Ltd.’s own tally for this item (“Elect Director: Peter Kolchinsky, Ph.D.”): 130,188,145 for, 444,723 against, per its Form 8-K filed August 11, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 55 asset managers below reported 28,274,570 for, 6,157 abstained.

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

Description as filed by funds: To approve the scheme of arrangement under Singapore law among Wave Life Sciences Ltd., a public company limited by shares incorporated under the laws of the Republic of Singapore ("Wave- Singapore"), the shareholders of Wave-Singapore and Wave Life Sciences, Inc., a Delaware corporation, subject to approval of the High Court of the Republic of Singapore, as set forth in Wave- Singapore's notice of, and proxy statement relating to, the Special Meeting of Wave-Singapore shareholders.

The 57 asset managers below reported 37,821,859 for, 16,522 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

Description as filed by funds: To authorize the Board of Directors to allot and issue Ordinary Shares of Wave Life Sciences Ltd.

Wave Life Sciences Ltd.’s own tally for this item (“5. A general authorization for the directors of the Company to allot and issue ordinary shares of the Company, in the manner and on the basis set forth in the Proxy Statement, with the final votes cast”): 102,173,940 for, 28,413,704 against — passed, per its Form 8-K filed August 11, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 5 - Shareholders approved a general authorization for the directors of the Company to allot and issue ordinary shares of the Company, in the manner and on the basis set forth in the Proxy Statement, with the final votes cast as follows:”
Support: 78% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Wave Life Sciences Ltd.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Approve Issuance of Shares without Preemptive Rights” (3 managers, 396,729 for).

The 54 asset managers below reported 25,699,836 for, 1,927,343 against, 16,819 abstained.

Showing the 25 largest of 54 asset managers. See all 54 in the interactive database.

Description as filed by funds: To approve our payment of cash and equity-based compensation to non-employee directors for service on the Board of Directors and its committees, in the manner and on the basis set forth under "Proposal 3: Non-Employee Directors' Compensation" in the proxy statement.

Wave Life Sciences Ltd.’s own tally for this item (“3. The Company's payment of cash and equity-based compensation to the Company's non-employee directors for their service on the Board of Directors and its committees, in the manner and on the basis set forth in the Proxy”): 130,474,503 for, 155,613 against — passed, per its Form 8-K filed August 11, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 - Shareholders approved the Company's payment of cash and equity-based compensation to the Company's non-employee directors for their service on the Board of Directors and its committees, in the manner and on the basis set forth in the Proxy Statement, with the final votes cast as follow…”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 28,078,642 for.

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

Description as filed by funds: To approve a proposed amendment to our 2021 Equity Incentive Plan, as amended, in the manner and on the basis as set forth under "Proposal 4: Approval of an Amendment to the 2021 Equity Incentive Plan, as amended" in the proxy statement.

Wave Life Sciences Ltd.’s own tally for this item (“4. The amendment to the Company's 2021 Equity Incentive Plan, as amended, in the manner and on the basis set forth in the Proxy Statement, with the final votes cast”): 105,936,049 for, 24,647,485 against — passed, per its Form 8-K filed August 11, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 4 - Shareholders approved the amendment to the Company's 2021 Equity Incentive Plan, as amended, in the manner and on the basis set forth in the Proxy Statement, with the final votes cast as follows:”
Support: 81% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Wave Life Sciences Ltd.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Omnibus Stock Plan” (3 managers, 396,729 against).

The 55 asset managers below reported 26,927,881 for, 727,825 against, 6,157 abstained.

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

Description as filed by funds: To approve, by a non-binding advisory vote, the compensation of our named executive officers as disclosed in the proxy statement

Wave Life Sciences Ltd.’s own tally for this item (“6. On a non-binding, advisory basis only, the compensation of the Company's named executive officers, in the manner and on the basis set forth described in the Proxy Statement, with the final votes cast”): 129,648,036 for, 977,466 against — passed, per its Form 8-K filed August 11, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 6 - Shareholders approved on a non-binding, advisory basis only, the compensation of the Company's named executive officers, in the manner and on the basis set forth described in the Proxy Statement, with the final votes cast as follows:”
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 54 managers: 28,009,679 for, 12,891 against, 18,157 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 151 managers: 100,683,077 for, 296,114 against, 940 not voted, 42,048 1 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: TO APPROVE, ON A NON-BINDING, ADVISORY BASIS ONLY, THE FREQUENCY OF HOLDING FUTURE SHAREHOLDER ADVISORY VOTES ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 53 managers: 448,282 for, 6,157 abstained, 27,177,559 1 year, 12,000 unknown. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 150 managers: 2,251,912 for, 940 not voted, 93,207,520 1 year, 314,256 3 year, 15,000 unknown. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To approve the re-appointment of KPMG LLP to serve as our independent registered public accounting firm and independent Singapore auditor for the year ending December 31, 2025, and to authorize the Audit Committee of the Board of Directors to fix KPMG LLP's remuneration for services provided through the date of our 2026 Annual General Meeting of Shareholders.

Wave Life Sciences Ltd.’s own tally for this item (“2. The re-appointment of KPMG LLP to serve as the Company's independent registered public accounting firm and independent Singapore auditor for the year ending December 31, 2025, and to authorize the Audit Committee of t”): 144,541,282 for, 619,542 against — passed, per its Form 8-K filed August 11, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 - Shareholders approved the re-appointment of KPMG LLP to serve as the Company's independent registered public accounting firm and independent Singapore auditor for the year ending December 31, 2025, and to authorize the Audit Committee of the Board of Directors to fix KPMG LLP's remuner…”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 55 asset managers below reported 28,034,570 for, 6,157 abstained.

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.